About the Study

B-cell acute lymphoblastic leukemia (B-ALL): A study of blinatumomab added to standard chemotherapy in patients with or without down syndrome

This study is available for patients ages 1 to 10 with B-ALL. Those ages 1 to 31 with down syndrome and B-ALL are eligible to participate. Patients with B-LLy (with or without down sydrome) and are 1 to 31 years old are also eligible. In this study, we will collect information about participants' leukemia and their response to Induction therapy. We will also compare the effects, good and/or bad, of blinatumomab when added to standard chemotherapy.

Interested in learning more?

Full Study Name: AALL1731 - A Phase 3 Trial Investigating Blinatumomab in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)